MediCrops acquires Swiss Alpinopharma
29.09.2023 10:38
The internationally operating Swiss health-tech company MediCrops Holding AG has acquired Berlin-based Swiss Alpinopharma GmbH, a disruptive market leader in the field of medical cannabis and owner of the telemedicine platform Enmedify. Swiss Alpinopharma also offers doctors CME-certified training in the use of medical cannabis. Through the acquisition, MediCrops strengthens its position in a European market that is expected to grow to 4.5 billion euros by 2026.
A pioneer in Germany and Switzerland
Swiss Alpinopharma is the first and only Swiss company to successfully bring medicines onto the market in Germany, the largest medical cannabis market in Europe. Sales in the medical cannabis market in Germany will be approximately 313 million euros in 2023.
With a number of medical cannabis medicines that have already been successfully launched, Swiss Alpinopharma has already proven its quality and expertise. The company is also the owner of the leading telemedicine platform Enmedify, which looks after a large number of patients every month with dozens of locations in Germany and relies on a broad network of doctors.
Complete digitization of the patient journey
MediCrops plans to digitize all steps of a patient journey. The acquisition of Swiss Alpinopharma, including the Enmedify platform, has brought us many times closer to this goal. “This acquisition is an important milestone in our vision to revolutionize medical cannabis treatment,” explains Ivan Mestrangelo, Chairman of the Board of Directors of MediCrops.
Secured funding and strong medical partnerships
MediCrops has already successfully completed two financing rounds worth almost CHF 20 million and is supported by a broad shareholder base including leading doctors from Switzerland. These medical partners will play a key role in implementing a health tech ecosystem.
Confidential handling of patient data
MediCrops' digital corporate strategy places the highest value on protecting patients' health data. State-of-the-art technologies and strict security protocols ensure that patient data is handled in accordance with global data protection regulations, including GDPR.
Shared vision for a digital cannabis ecosystem
Both MediCrops and Swiss Alpinopharma are actively involved in the creation of a digital cannabis ecosystem and work closely with the Swiss interest group IG MedCann and the German industry association Cannabiswirtschaft eV.